ATHE
NASDAQAlterity Therapeutics Limited
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$4.96+1.37 (+38.16%)
2026-04-142026-07-17
News · 26 weeks64-27%
2026-01-182026-07-12
Mix3990d
- SEC Filings27(69%)
- Other7(18%)
- Insider3(8%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol — – FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA – – Pivotal Phase 3 trial activities on track to initiate by year-end 2026 – MELBOURNE, Australia and SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received the official meeting minutes fr
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- INSIDERSEC Form 4 filed by Director Babarczy Julian Michael4 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)
- INSIDERSEC Form 4 filed by Director Gozlan Lawrence Bernard4 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- ANALYSTLadenburg Thalmann resumed coverage on Alterity Therapeutics with a new price targetLadenburg Thalmann resumed coverage of Alterity Therapeutics with a rating of Buy and set a new price target of $10.00
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration – – FDA agrees on UMSARS Part I as primary endpoint after ATH434 demonstrated 48% slowing of disease progression versus placebo in Phase 2 study – – FDA agrees with 50mg dose level which achieved clinically and statistically significant efficacy in Phase 2 study – – Pivotal Phase 3 trial activities on track to initiate by year-end 2026 – MELBOURNE, Australia and SAN FRANCISCO, June 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, trading under the ASX code ATHDA until 12 June, NASDAQ:ATHE) ("Alterity" or
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy– Alterity's novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – – End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – MELBOURNE, Australia AND SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company's development program in Multiple System Atrophy (MSA) were delivered at three medical conferences showcasing Alterity's novel imaging and biomarker approach, promisi
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in patients with Multiple System Atrophy (MSA) – – Findings support QSM as an objective imaging biomarker to enable earlier diagnosis and assess iron-modulating therapies in MSA, including Alterity's lead candidate ATH434 – MELBOURNE, Australia and SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the
- SECSEC Form 6-K filed by Alterity Therapeutics Limited6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
- PRAlterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company's development program in Multiple System Atrophy (MSA) will be delivered at multiple medical conferences in May 2026. The International Society for Magnetic Resonance in Medicine 2026 ISMRM and ISMRT Annual Meeting and Exhibition Title: Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation in Early MSA (Abstract #03335)Type: Oral PresentationPresenter: Pau
ATHE FAQ
6 questionsWhat does Alterity Therapeutics Limited do?
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.Where does ATHE stock trade?
Alterity Therapeutics Limited (ATHE) is listed on NASDAQ.What sector and industry is ATHE in?
Alterity Therapeutics Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ATHE?
Alterity Therapeutics Limited has had 4 recent analyst actions on file. The most recent action was from Ladenburg Thalmann: Buy with a $1000.00 price target on 2026-06-16. Recent price targets range from $400.00 to $1000.00.What companies are similar to ATHE?
Notable peers in the same industry include ACRS (Aclaris Therapeutics Inc.), RUBY (Rubius Therapeutics Inc.), ONTX (Onconova Therapeutics Inc.). Compare ATHE side-by-side with any of them on Quantisnow.How can I track ATHE on Quantisnow?
Quantisnow aggregates Alterity Therapeutics Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATHE to receive live email and push alerts on every new disclosure.